# Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)

> **NCT02598193** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 89 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** Nintedanib
- **DRUG:** Pirfenidone

## Key facts

- **NCT ID:** NCT02598193
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-14
- **Primary completion:** 2017-05-16
- **Final completion:** 2017-05-16
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2018-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02598193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02598193, "Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02598193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*